Shots: The companies collaborated to evaluate the Evaxion’s EVX-01 + MSD’s Keytruda in P-IIb study in patients with metastatic melanoma stage III & IV. The trial is expected to start […]readmore
Shots: Marinomed to receive $2M up front & is eligible to receive milestones upon achievement of development, regulatory & commercial milestones along with royalties on sales of Budesolv in Greater […]readmore
Shots: Incyte will lead the development, manufacture, and supply of both products. ST will be responsible for the regulatory, distribution, and local marketing related activities in Australia, New Zealand & […]readmore
Shots: LCB will be eligible to receive up front and milestones along with royalties & is eligible to receive a prespecified percentage of any sublicensing income received by Antengene, if […]readmore
Shots: BehaVR to receive $5M up front, ~$18M in development milestone and R&D support along with commercial & operational support fees and is eligible to receive $140M in milestone upon […]readmore
Shots: Dana-Farber to receive up front & will be eligible to receive development and commercial milestones along with royalties on product sales SpringWorks has also entered into an SRA with […]readmore
Shots: OXB to receive $4.83M as an option exercise fee & ~$37.96M in development, regulatory & sales milestones along with royalty on sales of a CF gene therapy product under […]readmore
Shots: Takeda is eligible to receive $10M up front in addition to $35M in Calithera Series A preferred stock and is eligible to receive clinical development, regulatory, and sales milestone […]readmore
Shots: Wave to receive $22.5M for research & preclinical expenses and is eligible to receive opt-in payment, development & commercial milestone & will lead the manufacturing & joint clinical co-development […]readmore
Shots: Lipocine to receive $11.0M up front, $5.0M as licensing fees in Jan’25 & $5.0M in Jan’26, ~$160.0M as sales-based commercial milestone based on Tlando net sales, if Antares exercises […]readmore